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Background
The rapidly put-on-treatment in acute HIV infection
(AHI) seems to achieve functional cure in up to
15% cases. This represents a huge difference, sponta-
neous elite-controllers being less than 0.5%.
Objective: To identify the AHI patients and to observe
the immune-virological course under immediately-
started antiretroviral treatment (ART).
Methods
All newly-diagnosed HIV-infected adults (>18 yo) in the
last 18 months (01.2013-06.2014) in an infectious dis-
eases hospital were considered. The including criteria
for AHI group were: detectable HIV-RNA or positive
antigen/antibody combination assays in the setting of a
negative/indeterminate HIV Western blot. AHI group
was classified accordingly to Fiebig stages and was
further evaluated regarding CD4 count and viral load
(VL) at diagnosis, at 3 and 6 months. ART initiation
and the regimen were also registered.
Results
804 adults were newly-diagnosed HIV-positive, out of
which 26 patients (2.32%) with AHI. The number of
patients in Fiebig II/III, IV, V and VI stages was 8, 15, 2
and 1 respectively. The AHI-group had a median age of
31, IQR [25-34] and 3.1:1 male:female ratio. The median
CD4 count was 435, IQR [251-775] and the median VL
was 5.6 log10, IQR [4.7-7]. Eight out of 26 AHI patients
immediately started ART, in Fiebig II/III and IV stages
for 7 of them. The 8th received ARV treatment in eclipse
phase (for 28 days, as post-exposure prophylaxis) then
restarted ART in Fiebig VI stage, at diagnosis moment.
The immediately-treated group had a median age of 24,
IQR [20-29], a male:female ratio of 7:1 and all were
symptomatic. The median CD4 count at diagnosis was
261, IQR [147-467] and the median VL was 7 log10, IQR
[5.6-7], except the partially-treated in eclipse-phase
patient, whose CD4 count was 789 and VL was 21977c/
mL at diagnosis. In the immediately-treated group there
was a rise in median CD4 count to 646, IQR [544-764] at
month 3 and to 755, IQR [577-950] at month 6. The
median VL declines to 1.6 log10, IQR [1.3-2.2] at
month 6. Five patients received a 3-drugs regimen and 3
received a 4-drugs regimen. The immune-virological
course couldn’t be correlated with a particular regimen
or with the number of drugs used.
Conclusion
Two percent of newly diagnosed HIV-infected patient in
18 months in our setting had AHI and one third of
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them received immediate treatment. The short-term
benefit was the consistent immune-virological improve-
ment, regardless of ART scheme. However, more than
half had detectable VL at month 6, probable due to the
very high initial VL.
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